Pales diabetes intro Flashcards
Diabetes Mellitus
Cluster of heterogeneous disorders with elevated blood glucose levels as a common diagnostic feature
Type 1
Type 2
Other
Insulin effect – anabolic effect
Stimulates: glucose transport, glycolysis, glycogen synthesis, amino acid transport, protein synthesis, triglyceride uptake, lipogenesis
inhibits:
glycogen breakdown, gluconeogenesis, protein breakdown, lipolysis, fatty acid oxidation
Type 1 DM
Associated with autoimmune antibodies
Likely T-Cell mediated
Requires environmental trigger
Mechanism is still not clearly understood
Antibodies in type 1 diabetes
Glutamic acid decarboxylase 65 (GAD 65) Insulin antibodies (IAA) Islet cell (ICA) Zinc transporter 8 (ZnT8) Tyrosine phosphatase (IA-2)
HLA-DR3, DR4
Type 1 DM. Prognosis
In the absence of renal disease, life expectancy in the United States is comparable to that of the general population.
Mortality rate of all type 1 diabetic patients from age 35 onward is about twice as high as in non-diabetics
Large reductions in the incidence of diabetes-related complications between 1990 and 2010 in the U.S due to change in management
Type 2 DM. Epidemiology
One of the most common chronic diseases,
25 million people in the US.
Prevalence increasing
Higher among Adults 65 years and older
Non-Hispanic blacks
Hispanics
American Indians
Type 2 DM. Mechanisms
Impaired Insulin Secretion
- Decreased b-Cells Mass
- Decreased glucose sensing by b-Cells
Impaired Insulin Action (Insulin resistance)
- In peripheral tissues- reduced glucose uptake in muscle and fat
- In the liver- Reduced suppression of hepatic glucose production.
Associated with:
Obesity
Metabolic syndrome
Polycystic ovary syndrome.
Type 2 DM. Genetics
Polygenic and multifactorial
More than 50 genetic risk loci identified which explain only 15% of the heritability
Emerging evidence of epigenetic changes playing a role (modification of gene expression)
“Metabolic programming” may occur in utero, with both fetal starvation and fetal overnutrition predisposing to diabetes in adult life.
DM Type 2 and Obesity
Obesity is the single most important clinical predictor of type 2 diabetes
There is a linear relationship between BMI and type 2
Related factors increasing risk
- Sedentary lifestyle
- Diet high in high-glycemic index food, transand saturated fats
- Visceral adiposity (including NASH)
DM Type 2 and Obesity. Suggested mechanisms
Increase in circulating FFA interferes with Insulin action in muscles and liver
Adipose tissue macrophages produce pro-inflammatory cytokines, which can interfere with insulin signaling.
Reduced levels of the fat-derived peptide diponectin, (has both anti-inflammatory and insulin-sensitizing properties).
Lipid accumulation in pancreatic islets may lead to impaired insulin secretion.
Metabolic Syndrome
2 physical findings and 3 labs
Waist circumference > 40 inches in men
> 35 inches in women
Hypertension > 130/85 mmHg
Triglycerides > 150 mg/dL
HDL-C under 40 mg/dL in men
under 50 mg/dL in women
Glucose > 100 mg/dL
differences betw Type I and Type II
Type I: onset in childhood, relatively rare, onset acute and severe, very low insulin secretion and normal insulin sensitivity, permanent insulin dependence, all racial groups, mostly sporadic cases, no acanthosis nigricans, autoimmune etiology, goes with other autoimmune and endocrine conditions
Type II: pubertal onset, most diabetes, often insidious onset, variable insulin secretion, decreased sensitivity, temporary insulin dependence, groups of color at more risk, strong genetic component (polygenic), ACANTHOSIS NIGRICANS, not autoimmune, goes with hypertension, dyslipidemia, metabolic syndrome, polycystic ovary syndrome
MODY
mature onset diabetes of hte young
MODY 3 is most common
usually good control with sulfonylurea
usually monogenetic
differences between one patient’s example of MODY and type 1
strong family history (2 or 3 generations)
no ketoacidosis when off insulin for 3 weeks
negative pancreatic autoantibodies
detectable C-peptide levels
comparison between type 2 and MODY
type 2: polygenic, usually over 40 years, rarely seen across generations, variable penetrance, usually obese, usually have metabolic syndrome
MODY- monogenic, autosomal dominant. Usually under 25 years old, seen across generations, 80-90% penetrance, non-obese, no metabolic syndrome
what is the main factor in MODY?
The MODY syndromes involve impaired glucose induced secretion of insulin
and most work by abnormal nuclear transcription factors .
MODY 5 is associated with
renal cysts, genital tract malformations and hyperuruicemia
Other Types of Diabetes rather than Type 1, Type 2, MODY
- Mutant insulins (rare), and mutant Insulin receptors (Acanthosis Nigricans and extreme insulin resistance).
- Mutation of Mitochondrial DNA – abnormal tRNA gene with beta-cell failure– hearing loss – resembles type 1 – no autoimmunity.
- Wolfram syndrome – DIDMOAD – altered endoplasmic reticulum of beta-cell protein leading to apoptosis.
- Autosomal Recessive syndromes – Pancreatic transcription factors - neonatal or childhood - Mitchell-Riley syndrome
DM secondary to other causes
- Endocrinopathies (the Omas, eg. glucagonoma)- tumors secreting GH, catecholamines, glucagon, glucocorticoids, and somatostatin.
- Immune mediated – receptor antibodies, “Stiffman syndrome”
- Medications – cyclosporine, tacrolimus, steroids, thiazides, beta-blockers, olanzopine
- Diseases of the exocrine pancreas – pancreatitis, cystic fibrosis, etc
- Infections – CMV, congenital Rubella
- Other genetic syndromes – Downs, Turners, Klinefelters, Friedreich’s ataxia
Drugs producing Hyperglycemia
Banting HAS TO PIN
Beta blockers
Hormones (glucocortoids, glucagon, GH), HAART (PIs, NRTI)
Hyperstat (diazoxide)
Alcohol, Antipsychotics (resperidone, quetipine, olanzapine)
Sympathomimetics (norepinephrine or epinephrine), Statins
Thiazides, Tricyclics
Oral contraceptives, Opiates,
Phenytoin, Pentamidine
Indocin, Isoniazid, and Immunosuppressants (cyclosporine,
tacrolimus, sirolimus, calcineuron inhibitors)
Niacin
Diagnosis of DM
Normal:
Fasting plasma glucose (FPG) under 100 mg/dL
Two-hour glucose during OGTT under 140 mg/dL (7.8 mmol/L).
HbA1c under 5.7
Pre-diabetes:
Impaired fasting glucose (IFG)
Fasting plasma glucose between 100 and 125 mg/dL.
Impaired glucose tolerance (IGT)
Two-hour plasma glucose value during a 75 g oral glucose tolerance test between 140 and 199 mg/dL.
HbA1C— persons with 5.7 to 6.4 percent are at highest risk
Diabetes mellitus :
On two different occasions FPG at or above 126 mg/dL
Two-hour value in an OGTT (2-h PG) at or above 200 mg/dL
On two different occasions random plasma glucose concentration ≥200 mg/dL in the presence of symptoms
If 2 of the above present, no need for two separate occasions
HbA1c – >6.4
Clinical Manigestation of DM
Could be asymptomatic Polydipsia Polyuria Weight Loss Acute complications of Diabetes Chronic Complications of Diabetes
Diabetic Ketoacidosis (DKA)
Hyperglycemia > 250 mg/dL
Acidosis with blood pH under 7.3
Serum bicarbonate under 15 mEq/L
* Serum positive for ketones (not just urine ketones)
DKA develops when?
Only develops in the insulin deficient states
Type I DM:
Usually initial presentation
Insulin non-compliance
Increase in anti-insulin hormones (cortisol etc) during stress (infection, surgery etc.)
Type II DM:
Late stages of Beta-Cells failure
During stress
(super high glucose can also shut down pancreatic insulin producing cells)